Puma Biotechnology Inc
$ 6.16
3.36%
26 Dec - close price
- Market Cap 310,409,000 USD
- Current Price $ 6.16
- High / Low $ 6.22 / 5.81
- Stock P/E 8.32
- Book Value 2.29
- EPS 0.74
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.40 %
- 52 Week High 6.22
- 52 Week Low 2.58
About
Puma Biotechnology, Inc. is a Los Angeles-based biopharmaceutical company dedicated to developing and commercializing innovative cancer therapies aimed at enhancing patient outcomes worldwide. The company utilizes precision medicine to advance a proprietary pipeline of drug candidates targeting distinct oncological conditions, addressing significant unmet needs within the oncology market. With a strong focus on research and development and a commitment to expanding its impactful therapeutic offerings, Puma Biotechnology is strategically poised to emerge as a key player in the evolving cancer therapeutics sector, representing a promising investment opportunity for institutional investors interested in transformative healthcare solutions.
Analyst Target Price
$3.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-07 | 2025-04-30 | 2025-02-26 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-29 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-02 |
| Reported EPS | 0.21 | 0.15 | 0.1 | 0.43 | 0.41 | -0.09 | -0.1 | 0.26 | 0.12 | 0.05 | 0.03 | -0.12 |
| Estimated EPS | 0.155 | 0.09 | -0.22 | 0.14 | 0.35 | -0.13 | -0.22 | 0.3 | 0.08 | 0.01 | -0.07 | 0.01 |
| Surprise | 0.055 | 0.06 | 0.32 | 0.29 | 0.06 | 0.04 | 0.12 | -0.04 | 0.04 | 0.04 | 0.1 | -0.13 |
| Surprise Percentage | 35.4839% | 66.6667% | 145.4545% | 207.1429% | 17.1429% | 30.7692% | 54.5455% | -13.3333% | 50% | 400% | 142.8571% | -1300% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PBYI
2025-12-23 12:09:53
Puma Biotechnology, Inc. has been included in the Nasdaq Biotechnology Index (NASDAQ: NBI), effective December 19, 2025. This inclusion recognizes Puma's commercial and clinical progress, including sustained demand for NERLYNX® and advancing development of alisertib. The company believes this milestone will enhance its visibility within the biotechnology investment community, delivering value for patients and shareholders.
2025-12-23 07:08:55
Puma Biotechnology, Inc. (NASDAQ: PBYI) has been added to the Nasdaq Biotechnology Index (NBI), effective December 19, 2025. This inclusion recognizes Puma's commercial execution, profitability, and clinical progress, particularly with NERLYNX® and alisertib. The NBI tracks biotechnology and pharmaceutical companies on The Nasdaq Stock Market, requiring them to meet specific eligibility criteria.
2025-12-18 13:11:26
This article compares two small-cap biotech companies, CorMedix (CRMD) and Puma Biotechnology (PBYI), to determine which offers a better investment opportunity. CorMedix, with its newly approved DefenCath and recent acquisition of Melinta Therapeutics, shows strong growth potential and a "Strong Buy" Zacks Rank. Puma Biotechnology, relying heavily on Nerlynx for breast cancer treatment, faces higher competitive risks and holds a "Hold" Zacks Rank, making CorMedix the more compelling choice for investors.
2025-12-13 08:08:39
Acorn Capital Advisors LLC increased its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 4.9% during the second quarter, bringing its total stake to $14.17 million. This makes Puma Biotechnology the firm's fourth largest position, representing 9.3% of its portfolio. Other institutional investors have also adjusted their positions in the biopharmaceutical company, which has seen its stock perform strongly recently.
2025-12-09 15:09:25
Puma Biotechnology (NASDAQ:PBYI) has shown impressive annual EPS growth of 48% over the last three years, despite a 13% drop in revenue last year. The company's EBIT margins improved from 14% to 16%, and insiders hold a significant US$41m worth of shares, representing 15% of the shares on issue. This combination of strong EPS growth and substantial insider investment suggests a potential opportunity for investors.
2025-11-24 04:42:16
Hillsdale Investment Management Inc. has acquired a new stake of 84,800 shares in Puma Biotechnology (NASDAQ:PBYI), valued at approximately $291,000. This investment makes Hillsdale Investment Management Inc. the owner of about 0.17% of Puma Biotechnology. Other institutional investors, such as LSV Asset Management, have also increased their positions, bringing the total institutional ownership to 61.29% of the company's stock, while an insider recently sold 20,000 shares.
